Cargando…

P737: LENZILUMAB AND AZACITIDINE IMPROVE HEMATOLOGIC ALTERATIONS OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE PREACH-M TRIAL

Detalles Bibliográficos
Autores principales:	Ross, David, Hiwase, Devendra, Lane, Steven, Sharplin, Kirsty, Yong, Agnes, David, Yeung, Chappell, Dale, Durrant, Cameron, Hughes, Timothy, Thomas, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429006/ http://dx.doi.org/10.1097/01.HS9.0000969852.23114.6d

Ejemplares similares

1134. Lenzilumab Treatment in COVID-19 Pneumonia Reduces Circulating Cytokines and Markers of Systemic Inflammation
por: Chappell, Dale, et al.
Publicado: (2022)

C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL
por: TEMESGEN, ZELALEM, et al.
Publicado: (2021)

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
por: Temesgen, Zelalem, et al.
Publicado: (2022)

GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study
por: Temesgen, Zelalem, et al.
Publicado: (2020)

A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data
por: Sharplin, Kirsty, et al.
Publicado: (2023)

C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial
por: Temesgen, Zelalem, et al.
Publicado: (2023)

LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
por: Temesgen, Zelalem, et al.
Publicado: (2021)

Azacitidine in Chronic Myelomonocytic Leukemia: An Effective and Manageable Approach
por: Tendas, Andrea, et al.
Publicado: (2014)

40. Lenzilumab Efficacy and Safety in Newly Hospitalized COVID-19 Subjects: Results From a Phase 3 Randomized Double-Blind Placebo-Controlled Trial
por: Temesgem, Zelalem, et al.
Publicado: (2021)

A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of Literature
por: Elli, Elena, et al.
Publicado: (2012)

Successful long-term treatment with azacitidine in patient with chronic myelomonocytic leukemia
por: Čemažar, Luka, et al.
Publicado: (2020)

An unusual response to 5‐azacitidine by a patient with chronic myelomonocytic leukemia
por: Islam, Anwarul
Publicado: (2023)

Physiology of Preaching
Publicado: (1871)

Physiology of Preaching
Publicado: (1869)

Preaching in Paris
Publicado: (1873)

Medical Preaching
Publicado: (1873)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
por: Aroldi, Andrea, et al.
Publicado: (2021)

Commentary: Preaching to the wire
por: Muller Moran, Hellmuth R., et al.
Publicado: (2020)

How to Preach Effectively
Publicado: (1855)

A Preach to Preachers
Publicado: (1871)

Vaccine advertising: preach to the converted or to the unaware?
por: Krupenkin, Masha, et al.
Publicado: (2021)

In Reply — Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
por: Temesgen, Zelalem, et al.
Publicado: (2021)

Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019
por: Melody, Megan, et al.
Publicado: (2020)

Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines
por: Kutyna, Monika M., et al.
Publicado: (2023)

Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia
por: Niscola, Pasquale, et al.
Publicado: (2015)

A Preaching Match: The Sunday Fund
Publicado: (1887)

Health Tract, No. 238: Preaching Easily
Publicado: (1866)

Successful management of therapy‐related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil
por: Nakako, Soichiro, et al.
Publicado: (2021)

PB2033: ADVANCED CHRONIC MYELOMONOCYTIC LEUKEMIA IN ELDERLY AND FRAIL PATIENTS MANAGED BY AZACITIDINE IN THE FIELD OF CLINICAL PRACTICE.
por: Niscola, Pasquale, et al.
Publicado: (2023)

Autistic-Undisciplined - Practice What You Preach!
por: Rushton, D. Hugh, et al.
Publicado: (2019)

Antibiotic Stewardship: Easy to Preach, Difficult to Practice
por: Hegde, Ashit
Publicado: (2021)

Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
por: Helbig, Grzegorz, et al.
Publicado: (2019)

Is This a 737 Max Moment for Brolucizumab?
por: Rosenfeld, Philip J., et al.
Publicado: (2020)

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
por: Kenealy, Melita, et al.
Publicado: (2019)

Practicing what we preach for successful interprofessional education
por: Beuken, Juliëtte A., et al.
Publicado: (2021)

Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England
por: Kilcoyne, Adrian, et al.
Publicado: (2022)

P492: SAFETY AND EFFICACY OF LP-108 AS MONOTHERAPY AND COMBINED WITH AZACITIDINE IN PATIENTS WITH RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR ACUTE MYELOID LEUKEMIA
por: Koenig, Kristin, et al.
Publicado: (2023)

Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study
por: Xu, Yu, et al.
Publicado: (2022)

Person-first language: are we practicing what we preach?
por: Crocker, Amy F, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ghaodktc1kav6krpv4jv3ra2ll